Clinical Trial

Phase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above

Name: Phase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above — clinical trial record (NCT07289503)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The primary objective of this study is to evaluate the tolerability, reactogenicity and safety of a single injection of three dose levels of ABO1105 in adults aged 18 years or above.

Trial Details

NCT Number	NCT07289503
Lead Sponsor	Suzhou Abogen Biosciences Co., Ltd. Collaborators: Abogen Biosciences (Shanghai) Co., Ltd
Conditions	Respiratory Syncytial Virus
Enrollment	96 participants
Start Date	2025-05-27
Primary Completion	2025-09-04 (estimated)
Study Completion	2026-06-27 (estimated)
Updated on ClinicalTrials.gov	2025-12-17